The EQUIP study

A Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Itolizumab (EQ001) in Subjects With Moderate-to-Severe Uncontrolled Asthma

TRIAL OVERVIEW

Disease: Uncontrolled moderate to severe asthma

The EQUIP study is a Phase 1b randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of itolizumab in patients with uncontrolled moderate to severe asthma. In this 12-week multiple ascending dose study, patients will receive either itolizumab or placebo administered subcutaneously every two weeks (over 8 weeks) for a total of 5 doses with 4 weeks of follow-up. The primary endpoints of the study are to evaluate safety and tolerability of itolizumab in patients with uncontrolled moderate to severe asthma. The secondary endpoints include characterizing pharmacokinetics (PK), pharmacodynamics (PD), PK/PD relationship and clinical activity of itolizumab.